Evaluating systemic immune-inflammation index in patients with implantable cardioverter defibrillator for heart failure with reduced ejection fraction
PACE - Pacing and Clinical Electrophysiology, cilt.45, sa.2, ss.188-195, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 45 Sayı: 2
- Basım Tarihi: 2022
- Doi Numarası: 10.1111/pace.14436
- Dergi Adı: PACE - Pacing and Clinical Electrophysiology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, SportDiscus
- Sayfa Sayıları: ss.188-195
- Anahtar Kelimeler: intracardiac defibrillator, lymphocyte, neutrophil, platelet, systemic immune-inflammation index
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: Pro-inflammatory pathways play an important role in the follow-ups of patients with intracardiac defibrillators (ICDs) for heart failure (HF) reduced with ejection fraction (HFrEF). A newly defined index - the systemic immune-inflammation index (SII)—has recently been reported to have prognostic value in patients with cardiovascular disease. This study's aim is to evaluate the SII value regarding its association with long-term mortality and appropriate ICD therapy during a 10-year follow-up. Methods: This retrospective study included 1011 patients with ICD for HFrEF. The SII was calculated as the neutrophil—to—lymphocyte ratio × total platelet count in the peripheral blood. The study population was divided into two groups according to the SII's optimal cut-off value to predict long-term mortality. The long-term prognostic impact of SII on these patients was evaluated regarding mortality and appropriate ICD therapy. Results: The patients with a higher SII (≥1119) had significantly higher long-term mortality and appropriate ICD therapy rates. After adjustment for all confounding factors, the long-term mortality rate was 5.1 for a higher SII. (95% CI: 2.9–8.1). The long-term appropriate ICD therapy rate was 2.0 for a higher SII (95% CI: 1.4–3.0). Conclusion: SII may be an independent predictive marker for both long-term mortality and appropriate ICD therapy in patients with HFrEF.